10/29/2020 | News release | Distributed by Public on 10/29/2020 04:56
Addition of highly regarded scientist in the field of protein research creates industry-leading depth in protein misfolding diseases
TORONTO, Ontario and CAMBRIDGE, Mass.-October 28, 2020-ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, welcomes Dr. David Wishart, Distinguished University Professor in the Departments of Biological Sciences and Computing Science at the University of Alberta, to its Scientific Advisory Board (SAB). Identified as one of the world's most highly cited scientists for each of the past 7 years, Dr. Wishart brings more than three decades in protein folding and misfolding research to ProMIS, creating industry-leading depth in this area of therapeutic development for neurodegenerative and other diseases.
'The commitment and talent of our advisory board has been instrumental to the ongoing development of our broad portfolio of highly specific therapeutic, vaccine and diagnostic candidates,' said Eugene Williams, Executive Chairman of ProMIS Neurosciences. 'Dr. Wishart's world-recognized expertise in protein folding and misfolding combined with Dr. Neil Cashman's complementary leadership will place ProMIS among the most accomplished within this arena. Their combined expertise will advance our platform's application to an even broader scope of diseases caused by protein misfolding.'
Dr. Wishart will play a pivotal role in advising ProMIS on the application and further development of its drug discovery and development platform, which is uniquely capable of identifying the sequence and shape (conformation) of novel binding targets-called peptide antigens-on misfolded proteins implicated in the development of neurodegenerative diseases such as Alzheimer's, Parkinson's and ALS. ProMIS has leveraged its novel platform to create a portfolio of antibody, intrabody and vaccine candidates that are highly selective for the misfolded protein aggregates driving pathogenesis. With Dr. Wishart's support, ProMIS will continue to expand the application of its platform to the biology of additional misfolded protein diseases.
'Never before has there been a more urgent need for therapy, diagnostic and vaccine candidates that are highly specific for their intended target,' said Dr. Wishart. 'I look forward to working with Dr. Neil Cashman and his team and such an accomplished SAB as we continue to seek new opportunities to apply ProMIS' unique platform technology to misfolded protein diseases with high unmet need.'
ProMIS' SAB includes distinguished, highly published and cited contributors to the current scientific understanding of Alzheimer's, Parkinson's, ALS, protein misfolding diseases in general, vaccines and diagnostics. Dr. Wishart joins the following current members:
About Dr. David Wishart
Dr. Wishart has been studying protein folding and misfolding for more than 30 years using a combination of computational and experimental approaches. These experimental approaches include NMR spectroscopy, circular dichroism, fluorescence spectroscopy, electron microscopy, protein engineering and molecular biology. The computational methods include molecular dynamics, agent-based modeling, bioinformatics and machine learning. Over the course of his career, Dr. Wishart has published more than 430 scientific papers, cited more than 78,000 times, covering many areas of protein science including structural biology, protein metabolism and computational biochemistry. He has been with the University of Alberta since 1995 and is currently a Distinguished University Professor in the Departments of Biological Sciences and Computing Science. He also holds adjunct appointments with the Faculty of Pharmaceutical Sciences and the Department of Pathology and Laboratory Medicine.
Dr. Wishart has been awarded research grants totaling more than $130 million from a number of funding agencies. He has also led or directed a number of core facilities and centers and currently co-directs The Metabolomics Innovation Centre (TMIC), Canada's national metabolomics laboratory. Dr. Wishart held the Bristol-Myers Squibb Research Chair in Pharmaceutical Sciences from 1995-2005, received the Astra-Zeneca-CFPS Young Investigator Prize in 2001, was awarded a Lifetime Honorary Fellowship by the Metabolomics Society in 2014 and elected as a Fellow of the Royal Society of Canada in 2017.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of proteins. In neurodegenerative diseases, such as Alzheimer's, ALS and Parkinson's disease, the DSEs are misfolded regions on toxic forms of otherwise normal proteins. In the infectious disease setting, these DSEs represent peptide antigens that can be used as an essential component to create accurate and sensitive serological assays to detect the presence of antibodies that arise in response to a specific infection, such as COVID-19. ProMIS proprietary peptide antigens can also be used to create potential therapeutic antibodies, as well as serve as the basis for development of vaccines. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
Visit us at www.promisneurosciences.com, follow us on Twitterand LinkedIn. To learn more about protein misfolding diseases, listen to Episodes 11, 24, of Saving Minds, a podcast available at iTunesor Spotify.
For media inquiries, please contact:
Tel. 617 921-0808
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.